LBRX vs PFE · $803.4M cap vs P/E 20, rev $15.03B
LB Pharmaceuticals Inc Common Stock (LBRX) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
LB Pharmaceuticals Inc Common Stock (LBRX) is a biotechnology company listed on NASDAQ.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
LBRX does not have a complete income-statement cache yet.
Latest reported PFE revenue for 2026-06-28 was $15.03B. Net income was -$248.0M. Revenue was up 4.0% from 2026-03-29 to 2026-06-28. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
LBRX currently screens at market cap $803.4M. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the LBRX and PFE stock pages for the full models.
Not investment advice.